Achaogen, Inc. (AKAO) Analysts See $-0.92 EPS

July 11, 2018 - By Marie Mckinney

Achaogen, Inc. (NASDAQ:AKAO) LogoInvestors sentiment decreased to 1.02 in Q1 2018. Its down 0.30, from 1.32 in 2017Q4. It worsened, as 17 investors sold Achaogen, Inc. shares while 28 reduced holdings. 22 funds opened positions while 24 raised stakes. 25.38 million shares or 14.67% less from 29.75 million shares in 2017Q4 were reported.
Iguana Health Lc holds 100,000 shares or 0.85% of its portfolio. State Street Corp holds 3.10M shares. 59,600 were accumulated by Alliancebernstein Lp. Engineers Gate Manager Limited Partnership reported 97,817 shares stake. Moreover, Wells Fargo & Mn has 0% invested in Achaogen, Inc. (NASDAQ:AKAO). Jpmorgan Chase & invested in 0% or 10,578 shares. Quantitative Mgmt Ltd Liability Co owns 93,700 shares for 0.02% of their portfolio. Credit Suisse Ag reported 33,373 shares stake. Susquehanna Int Gp Llp, a Pennsylvania-based fund reported 102,305 shares. Stifel Financial holds 10,391 shares. Dekabank Deutsche Girozentrale holds 16,500 shares. Harbourvest Prtn Limited Com reported 20,000 shares stake. Deutsche Comml Bank Ag holds 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO) for 474,271 shares. Alyeska Invest Grp L P reported 198,214 shares stake. Bnp Paribas Arbitrage Sa stated it has 7,403 shares or 0% of all its holdings.

Since February 13, 2018, it had 10 insider buys, and 11 insider sales for $28.83 million activity. Shares for $798,322 were bought by DUGGAN ROBERT W. Schilke Tobin also sold $2,858 worth of Achaogen, Inc. (NASDAQ:AKAO) on Tuesday, June 26. Shares for $32,109 were sold by Hillan Kenneth J. on Tuesday, March 13. Another trade for 1,194 shares valued at $11,450 was made by Wise Blake on Tuesday, June 26. $3,107 worth of stock was sold by LOEB GARY on Tuesday, June 26. Another trade for 450 shares valued at $4,316 was made by Dorling Janet on Tuesday, June 26.

Analysts expect Achaogen, Inc. (NASDAQ:AKAO) to report $-0.92 EPS on August, 2.They anticipate $0.14 EPS change or 17.95 % from last quarter’s $-0.78 EPS. After having $-0.98 EPS previously, Achaogen, Inc.’s analysts see -6.12 % EPS growth. The stock increased 5.61% or $0.44 during the last trading session, reaching $8.29. About 1.02M shares traded. Achaogen, Inc. (NASDAQ:AKAO) has declined 48.54% since July 11, 2017 and is downtrending. It has underperformed by 61.11% the S&P500.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Coverage

Among 8 analysts covering Achaogen (NASDAQ:AKAO), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Achaogen had 11 analyst reports since February 14, 2018 according to SRatingsIntel. As per Wednesday, June 27, the company rating was maintained by Mizuho. The company was maintained on Wednesday, February 14 by Wedbush. The firm earned “Buy” rating on Wednesday, February 28 by Mizuho. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, February 28 report. The stock has “Outperform” rating by Wedbush on Wednesday, June 27. The rating was downgraded by Guggenheim on Monday, May 7 to “Neutral”. The company was maintained on Wednesday, February 28 by Needham. The rating was maintained by Needham with “Buy” on Tuesday, June 26. The stock of Achaogen, Inc. (NASDAQ:AKAO) has “Buy” rating given on Wednesday, May 2 by Cowen & Co.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $371.36 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

More notable recent Achaogen, Inc. (NASDAQ:AKAO) news were published by: Seekingalpha.com which released: “Achaogen: Zemdri To The Rescue” on July 10, 2018, also Benzinga.com with their article: “Achaogen In The Spotlight Ahead of FDA Verdict On Plazomicin” published on June 22, 2018, Seekingalpha.com published: “Key events next week – healthcare” on June 21, 2018. More interesting news about Achaogen, Inc. (NASDAQ:AKAO) were released by: Seekingalpha.com and their article: “Achaogen: Falling Knife Or Major Bargain?” published on June 28, 2018 as well as 247Wallst.com‘s news article titled: “Gogo, Real Goods Solar Topple into Monday’s 52-Week Low Club” with publication date: July 09, 2018.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>